Skip to main content
Clinical Trials/NCT06260228
NCT06260228
Active, Not Recruiting
N/A

HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's)

Dartmouth-Hitchcock Medical Center1 site in 1 country10 target enrollmentJanuary 5, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Dartmouth-Hitchcock Medical Center
Enrollment
10
Locations
1
Primary Endpoint
Change in quality of life as measured by comparing PDQ-39 (Parkinson's Disease Questionnaire) scores pre- and post-HOBSCOTCH-PD intervention.
Status
Active, Not Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Parkinson's Disease (PD)

The main questions it aims to answer are:

  1. Can the current HOBSCOTCH program be adapted for people with PD?
  2. Will people with PD experience improved quality of life similar to that found in people with epilepsy after participating in the HOBSCOTCH program?

Participants will be asked to:

  • attend nine, one-hour virtual (online and/or by telephone) HOBSCOTCH-PD sessions with a one-on-one certified HOBSCOTCH-PD coach
  • complete a brief clinical questionnaire about their diagnosis of PD
  • complete two questionnaires before and after the HOBSCOTCH-PD sessions about their quality of life and about memory and thinking processes
  • keep a short daily diary about their PD symptoms and use of the self-management strategies taught in the HOBSCOTCH-PD program
  • complete a brief Satisfaction Survey after the entire HOBSCOTCH-PD program
Registry
clinicaltrials.gov
Start Date
January 5, 2024
End Date
July 30, 2026
Last Updated
4 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Elaine T. Kiriakopoulos

Assistant Professor of Neurology, Geisel School of Medicine at Dartmouth Director, HOBSCOTCH Institute for Cognitive Health & Well-Being Dartmouth Hitchcock Epilepsy Center

Dartmouth-Hitchcock Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age 30 - 75 years
  • Diagnosis of Parkinson's Disease per participant's provider
  • Literate, English-speaking with grade 12 or equivalent in education
  • Self-reported cognitive/memory difficulties
  • Telephone and internet access

Exclusion Criteria

  • Cognitive dysfunction that precludes participation in giving informed consent
  • Significant visual impairment precluding reading or writing
  • No reliable telephone or internet access

Outcomes

Primary Outcomes

Change in quality of life as measured by comparing PDQ-39 (Parkinson's Disease Questionnaire) scores pre- and post-HOBSCOTCH-PD intervention.

Time Frame: Baseline (pre-HOBSCOTCH-PD) and post-HOBSCOTCH-PD, approximately 9 weeks later.

The Parkinson's Disease Questionnaire (PDQ-39) is a 39-item validated, patient reported measure of quality of life. The questionnaire assesses how often people with PD experience difficulties across 8 dimensions of daily living including relationships, social situations and communication as well as the impact of Parkinson's on specific dimensions of functioning and wellbeing. The dimension scores are coded on a scale of 0 (perfect health as assessed by the measure) to 100 (worst health as assessed by the measure).

Change in subjective cognition as measured by comparing Neuro-QOL Item Bank v2.0 Cognitive Function scores pre- and post-HOBSCOTCH-PD intervention.

Time Frame: Baseline (pre-HOBSCOTCH-PD) and post-HOBSCOTCH-PD, approximately 9 weeks later.

The Cognitive Function sub-scale of the Neuro-QOL is a brief validated tool developed by the NIH for use in patients with neurological disease. Scores range from 8 to 40, with a higher score indicating better reported cognitive functioning.

Study Sites (1)

Loading locations...

Similar Trials